NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Q1 Loss Widening To US$64.5 Million Tests Profitability Narratives
Axsome Therapeutics (AXSM) Q1 2026 earnings snapshot
Axsome Therapeutics (AXSM) has opened 2026 with Q1 revenue of US$191.2 million and a basic EPS loss of US$1.26, alongside a net loss of US$64.5 million, setting a clear benchmark for how the rest of the year might look. The company has seen revenue progress from US$118.8 million in Q4 2024 to US$191.2 million in Q1 2026, while trailing twelve month EPS has moved from a loss of US$5.99 to a loss of US$3.74 as revenue reached US$708.2 million...